{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-24-000079","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.771286+00:00","generated_at":"2026-06-02T02:44:21.010279+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Centessa Q1 net loss $38M; initiates ORX750 Phase 1, cash runway into mid-2026","bullets":["Net loss of $38.0M, improved from $50.7M in Q1 2023; R&D expense $22.7M vs $32.8M.","Cash, equivalents, and short-term investments $230.2M as of March 31, plus $107.2M net from April/May ADS offering.","Phase 1 first-in-human trial of ORX750 (narcolepsy) initiated; proof-of-concept data expected 2H 2024.","SerpinPC registrational PRESent-2 interim analysis planned for 2024; Part 1 data to be shared late 2024/early 2025.","LB101 (PD-L1xCD47) Phase 1/2a for solid tumors ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-24-000079","json":"https://secwatch.observer/filing/0001847903-24-000079.json","markdown":"https://secwatch.observer/filing/0001847903-24-000079.md","text":"https://secwatch.observer/filing/0001847903-24-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000079/0001847903-24-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000079/cnta-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:44:21.010279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a1751333353d3ada51871cebf5c86c0bdd0cec5","claim":"Centessa Pharmaceuticals plc reported the first quarter ended March 31, 2024 results: net income $38.0 million.","evidence_excerpt":"Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000079/0001847903-24-000079-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$38.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}